Roth Capital Affirms Neuralstem (CUR) at 'Buy' Amid NSI-189 Enrollment Milestone

September 21, 2016 11:56 AM EDT
Get Alerts CUR Hot Sheet
Price: $0.32 --0%

Rating Summary:
    5 Buy, 1 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 8 | Down: 13 | New: 19
Trade CUR Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Roth Capital affirms Neuralstem (Nasdaq: CUR) with a Buy rating and $1.20 price target after the company announced that it has reached over 50% enrollment in its Phase 2 clinical trial evaluating NSI-189, a novel neurogenic small molecule, for the treatment of major depressive disorder (MDD).

Analyst Joseph Pantginis commented today, We believe that the timely achievement of 50% study enrollment in the Phase IIb trial highlights the efforts that CUR and management are making to keep the company focused on its lead compound, NSI-189. Importantly, the present enrollment rate keeps the target time for data release in 2H17. According to our projections, the additional funding from the September raise gives CUR ~1.5 years of runway.

For an analyst ratings summary and ratings history on Neuralstem click here. For more ratings news on Neuralstem click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, FDA

Related Entities

Roth Capital

Add Your Comment